| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1657* | 2020 |
| The evolutionary history of lethal metastatic prostate cancer G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, JMC Tubio, ... Nature 520 (7547), 353-357, 2015 | 1422 | 2015 |
| Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue CS Cooper, R Eeles, DC Wedge, P Van Loo, G Gundem, LB Alexandrov, ... Nature genetics 47 (4), 367-372, 2015 | 468 | 2015 |
| Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes JMC Tubio, Y Li, YS Ju, I Martincorena, SL Cooke, M Tojo, G Gundem, ... Science 345 (6196), 1251343, 2014 | 436 | 2014 |
| Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer YS Ju, LB Alexandrov, M Gerstung, I Martincorena, S Nik-Zainal, ... elife 3, e02935, 2014 | 393 | 2014 |
| Structural basis for the nuclear import of the human androgen receptor ML Cutress, HC Whitaker, IG Mills, M Stewart, DE Neal Journal of cell science 121 (7), 957-968, 2008 | 297 | 2008 |
| Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study H Ross-Adams, AD Lamb, MJ Dunning, S Halim, J Lindberg, CM Massie, ... EBioMedicine 2 (9), 1133-1144, 2015 | 282 | 2015 |
| Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets DC Wedge, G Gundem, T Mitchell, DJ Woodcock, I Martincorena, M Ghori, ... Nature genetics 50 (5), 682-692, 2018 | 231 | 2018 |
| Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer R Morgan, A Boxall, A Bhatt, M Bailey, R Hindley, S Langley, HC Whitaker, ... Clinical Cancer Research 17 (5), 1090-1098, 2011 | 158 | 2011 |
| Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging MD Allen, P Luong, C Hudson, J Leyton, B Delage, E Ghazaly, R Cutts, ... Cancer research 74 (3), 896-907, 2014 | 133 | 2014 |
| LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals HJ Thirkettle, J Girling, AY Warren, IG Mills, K Sahadevan, H Leung, ... Clinical Cancer Research 15 (9), 3003-3013, 2009 | 121 | 2009 |
| Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress HC Whitaker, D Patel, WJ Howat, AY Warren, JD Kay, T Sangan, ... British journal of cancer 109 (4), 983-993, 2013 | 115 | 2013 |
| Five-year outcomes of magnetic resonance imaging–based active surveillance for prostate cancer: a large cohort study V Stavrinides, F Giganti, B Trock, S Punwani, C Allen, A Kirkham, ... European urology 78 (3), 443-451, 2020 | 112 | 2020 |
| Alterations in β‐catenin expression and localization in prostate cancer HC Whitaker, J Girling, AY Warren, H Leung, IG Mills, DE Neal The Prostate 68 (11), 1196-1205, 2008 | 102 | 2008 |
| N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype HC Whitaker, LL Shiong, JD Kay, H Grönberg, AY Warren, A Seipel, ... Oncogene 33 (45), 5274-5287, 2014 | 95 | 2014 |
| The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine HC Whitaker, Z Kote-Jarai, H Ross-Adams, AY Warren, J Burge, A George, ... PloS one 5 (10), e13363, 2010 | 93 | 2010 |
| Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression HJ Thirkettle, IG Mills, HC Whitaker, DE Neal Oncogene 28 (41), 3663-3670, 2009 | 88 | 2009 |
| What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS cohort JM Norris, LMC Echeverria, SRJ Bott, LC Brown, N Burns-Cox, ... European urology 78 (2), 163-170, 2020 | 78 | 2020 |
| The potential value of microseminoprotein‐β as a prostate cancer biomarker and therapeutic target HC Whitaker, AY Warren, R Eeles, Z Kote‐Jarai, DE Neal The Prostate 70 (3), 333-340, 2010 | 78 | 2010 |
| PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer S Luszczak, C Kumar, VK Sathyadevan, BS Simpson, KA Gately, ... Signal transduction and targeted therapy 5 (1), 7, 2020 | 70 | 2020 |
